e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Biologics may have a beneficial effect in asthma patients with COVID-19
José L. Izquierdo, Joan B. Soriano
Source:
Eur Respir J, 58 (2) 2101076; 10.1183/13993003.01076-2021
Journal Issue:
August
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
José L. Izquierdo, Joan B. Soriano. Biologics may have a beneficial effect in asthma patients with COVID-19. Eur Respir J, 58 (2) 2101076; 10.1183/13993003.01076-2021
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Education of the patients and its effect in asthma management
Source: Eur Respir J 2003; 22: Suppl. 45, 371s
Year: 2003
The impact of COVID-19 on patients with asthma
Source: Eur Respir J, 57 (3) 2003142; 10.1183/13993003.03142-2020
Year: 2021
Impact of omalizumab in patients with severe asthma
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009
Modelling the beneficial impact of inhaled corticosteroids on health outcomes among COPD patients
Source: Eur Respir J 2004; 24: Suppl. 48, 290s
Year: 2004
Evaluating the efficacy of omalizumab in severe persistent asthma patients
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
BTS Difficult Asthma Registry: Effect of omalizumab dosing table expansion on size of population of severe persistent allergic asthma patients potentially eligible for omalizumab therapy
Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma
Year: 2012
Ceruloplasmine efficacy in patients with asthma exacerbations
Source: Annual Congress 2011 - Novel mechanisms in lung injury
Year: 2011
Effect of asthma and asthma medication on the prognosis of patients with COVID-19
Source: Eur Respir J, 57 (3) 2002226; 10.1183/13993003.02226-2020
Year: 2021
Study of antioxidant use in patients with asthma exacerbations
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013
Anti-inflammatory effect of an additional therapy with Montelukast on steroid-dependent children with asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 492s
Year: 2001
The oral corticosteroid sparing effect of omalizumab in paediatric patients with severe chronic asthma
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010
Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
Cost effectiveness of omalizumab in Swedish asthma patients
Source: Eur Respir J 2006; 28: Suppl. 50, 441s
Year: 2006
Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy
Source: International Congress 2015 – Advances in the future treatment of COPD
Year: 2015
The role of proinflammatory cytokines in severe COPD patients before and after roflumilast treatment
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Which patients should be treated with anti-IgE?
Source: Eur Respir Rev 2007; 16: 85-87
Year: 2007
The effect of long-term treatment with erdosteine on moderate or severe COPD patients
Source: Eur Respir J 2005; 26: Suppl. 49, 292s
Year: 2005
Study of some inflammatory markers in children with moderate persistent bronchial asthma before and after therapy with inhaled corticosteroids
Source: Annual Congress 2013 –Monitoring asthma: genes, cells and molecules
Year: 2013
The role of IFN-γ in severe COPD patients with anamnestic viral-induced exacerbations before and after roflumilast treatment
Source: International Congress 2016 – Translational studies in lung disease
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept